US approves postpartum depression pill

US approves postpartum depression pill The US has approved the first pill for postpartum depression.

The Food and Drug Administration (FDA) said zuranolone, sold under the brand name Zurzuvae, has been approved as a once-daily pill taken for two weeks.

Until now, treatment for postpartum depression (PPD) was available only as an intravenous injection, the FDA said. BBC News

See also:

• FDA Approves First Oral Treatment for Postpartum Depression US Food and Drug Administration
• Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial (open access) JAMA Psychiatry